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Chnical and Laboratory Study of Sickle Cell/p-Thalassemia
Koichi Maeda, MD,* Ellis J. Van Slyck, MD,^ and Robert C. Hawley, MD'

We have studied 39 patients doubly heterozygous for sickle cell/^-thalassemia, 12 with sickle cell/^"thalassemia and 27 with sickle cell/^'''-thalassemia. Generally, sickle cell/^''-thalassemia is
considered more severe than sickle cell/^'''-thalassemia. In our study, however clinical complications
in the group with sickle cell/^'^-thalassemia were seen almost as frequently as in the group with sickle
cell/^"-thalassemia. A wide variety of clinical manifestations were seen in both groups of patients.
(Henry FordHosp MedJ 1986;34:282-4)

T

he double heterozygous condition, sickle cell/pthalassemia, is seen in whites (predominantly Greeks and
Italians) in the Mediterranean area of southern Europe, and
mainly in blacks in the United States (1-6). The disease is known
to manifest a variety of clinical symptoms, particularly vasoocclusive crises as well as other, more chronic complications
noted later Clinically, the cases may range from mild to severe,
the latter resembling sickle cell anemia (SS). Sickle cell/|3thalassemia has been subdivided into 1) sickle cell/p"'"thalassemia in which there is impaired but still significant
p-chain synthesis, and 2) sickle cell/p'^-thalassemia in which
there is no 3-chain production. The former condition is more
common in blacks and is considered clinically milder than the
latter condition (4,6,7). However, the clinical reports regarding
these two subgroups are relatively scarce. Furthermore, in our
practice we have seen patients with sickle cell/|3'^-thalassemia
suffering from several complications even though it is considered a milder disease. Our experience with both subtypes of
sickle cell/p-thalassemia has been fairly extensive and is the
basis for this report, which compares the two subtypes with respect to clinical and hematologic manifestations.

Materials and Methods
Thirty-nine patients with sickle cell/p-thalassemia were seen
at Henry Ford Hospital during the past ten years.
In general, patients with microcytic red cells, a predominance
of hemoglobin S, no hemoglobin A, variably increased hemoglobin AJ, and variably increased hemoglobin F were considered to have sickle cell/p°-thalassemia. Patients with microcytic
red cells, a predominance of hemoglobin S, a minor component
of hemoglobin A (in the absence of recent blood transfusion),
variably increased hemoglobin A^, and variably increased
hemoglobin F were considered to have sickle cell/P"'"thalassemia. Sickle cell/p"-thalassemia was distinguished from
sickle cell anemia by the presence of microcytosis and elevated
hemoglobin A, levels. In some cases confirmation was obtained
by family studies. Sickle cell/3°-thalassemia was distinguished
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from double heterozygocity for hemoglobin S and hereditary
persistence of fetal hemoglobin on clinical grounds as well as by
the presence of microcytosis and elevated hemoglobin A, levels.
Sickle cell/3"-thalassemia was differentiated from double heterozygocity for hemoglobin S and hemoglobin Lepore by acid
citrate agar electrophoresis.
All the patients' charts were reviewed. Complete blood counts
were determined by a Coulter Model S and S Plus electronic cell
counters. Hemoglobin analysis was done by cellulose acetate
electrophoresis using TRIS-EDTA acetate buffer at pH 9.2 and
citrate agar electrophoresis with sodium citric acid buffer at pH
6.2. Hemoglobin F was also measured by alkaline denaturation.
Hemoglobin A, was determined by column chromatography.
Student's t test and the Fisher exact test were used for comparison of the data.

Results
The patients' ages ranged from 1 to 81 years, with a mean of
28 years. Twelve patients were younger than 18 years of age. Of
the 39 patients, 22 were women and 17 were men. There were 36
blacks and three whites.
Hematologic data
The hemoglobin ranged from 5.7 to 15.1 g/dL, with a mean of
10.5 g/dL. The mean corpuscular volume ranged from 63 to
80.7 U \ with a mean of 72.3 U^. The average mean corpuscular
hemoglobin concentration was 32.6%. The reticulocyte count
was determined in 26 patients; the count ranged from 0.8% to
30.5%, and the mean was 6.4%.
Twelve patients had no hemoglobin A and were considered to
have sickle cell/p"-thalassemia. The remaining 27 patients had
hemoglobin A ranging from 8.7% to 26.8%, with a mean of
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Table 1
Hematological Data

Hemoglobin (g/dL)
Reticulocyte (%)
Hemoglobin S (%)
Hemoglobin A (%)
Hemoglobin F (%)
Hemoglobin A, (%)
MCV (U5)
MCHC(%)
Bilirubin (mg%)

Sickle Cell/3» Thalassemia
No.
Mean
Range

Sickle Cell/(3+ -Thalassemia
No.
Mean
Range

12
10
12
12
12
12
12
12
10

27
16
27
27
27
27
27
27
17

8.7
8.7
83.7
0
11.7
5.0
72.2
31.8
2.1

5.7-10.9
2.0-30.5
74.0-95.7
0
0.2-22.3
3.4-6.9

0.7-3.1

11.3
4.9
67.8
18.8
8.3
4.9
69.6
31.4
1.7

P-value

8.4-15.1
0.8-25.0
46.2-83.4
8.7-26.8
0.8-27.7
2.1-7.2

0.01
0.01
0.01

0.3-11.0

—

—
NS
NS
NS
NS

NS = not significant.

18.8%. The hemoglobin A, ranged from 2.1% to 7.2%, with a
mean of 4.9%. The hemoglobin F ranged from 0.2% to 27.7%,
with a mean of 9.3%. The hemoglobin S ranged from 46.2% to
95.7%, with a mean of 72.7%.
Total bilimbin was available in 27 patients. It ranged from 0.3
to 11.0 mg%, with a mean of 1.9 mg%.
Clinical findings
Thirty-two patients had painful episodes, seven had
hepatomegaly, one had a leg ulcer, 18 had joint pain, four had
cardiomegaly, and four had avascular necrosis of bone. Three of
the four patients with avascular necrosis of bone had involvement of the hip. Fifteen patients had splenomegaly, and two
patients had undergone splenectomy.
Other complications observed included two patients with dactylitis (periostitis of the small bones of the hands and feet), three
patients with thrombophlebitis of the leg, three patients with
cholelithiasis requiring cholecystectomy, and three patients
with retinal hemorrhages and detachments. In addition, sporadic pneumonia, upper respiratory infection, and urinary tract
infection were observed in some patients. Two patients with
sickle cell/p°-thalassemia died at 33 and 38 years of age, respectively. The death of the 33-year-old, a black woman, was due to
thrombophlebitis and congestive heart failure associated with
severe chronic anemia requiring multiple transfusions. The 38year-old, also a black woman, died of congestive heart failure
associated with anemia. A 19-year-old black man with sickle
cell/p'^-thalassemia is doing poorly with neurologic impairment
due to a stroke, poor vision, hematuria, and hemoptysis. A 26year-old woman with sickle cell/P"'"-thalassemia had autoimmune hemolytic anemia and iliofemoral thrombosis.
Ten of the 39 patients had a history of transfusions. Nine had
received transfusions for anemia, and one patient had received a
transfusion in preparation for hemia repair surgery. Five of the
nine who received transfusions for anemia were P'^-type and
four were p^-type. No patient received a transfusion in the period preceding hemoglobin electrophoretic study.
Sickle cell/p*-thalassemia versus sickle cell/p^-thalassemia
As previously described, 12 patients had sickle cell/p°thalassemia and 27 had sickle cell/p+-thalassemia. Laboratory
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and clinical results in these two groups are compared in Tables 1
and 2. There were statistically significant differences in certain
laboratory results. The mean hemoglobin level was lower and
the mean level of hemoglobin S and mean reticulocyte count
were higher in patients with sickle cell/p^-thalassemia. There
was no significant difference in the frequency of different
clinical manifestations except for cardiomegaly, which was
more frequent in p°-thalassemia.

Discussion
In our study sickle cell/P"''-thalassemia was more common
than sickle cell/p"-thalassemia. These findings are similar to
those reported from Jamaica (4,7), probably because most of our
patients were black, and blacks tend to carry the P"'' gene more
frequently than the P" gene. A variety of clinical manifestations
were observed in both groups of patients, including painful episodes, splenomegaly, joint pain with or without effusion,
hepatomegaly, avascular necrosis of bone, cardiomegaly, and
leg ulcers (4,6,8,9). When the group of patients with sickle
cell/p''"-thalassemia was compared to the group with sickle
cell/p"-thalassemia in terms of incidence of the different clinical
manifestations, there was no statistically significant difference
between the two groups except for cardiomegaly. Cardiomegaly
was more frequent in the group with sickle cell/p^-thalassemia.
Serjeant and Serjeant observed that the clinical course was more
severe in patients with sickle cell/p^-thalassemia than in patients
with sickle cell/P"'^-thalassemia (7). Since our statistical comparison was based on the incidence of the various complications,
we can neither discount nor support the conclusions of Serjeant
and Serjeant. After seeing early deaths in two patients and
severe clinical disease in a third patient with sickle
cell/p^-thalassemia, we certainly recognize that sickle cell/p°thalassemia can be a severe disease in some patients. What we
wish to emphasize is that frequent complications also can occur
in patients with sickle cell/P'''-thalassemia.
When laboratory data forthe two groups were compared, several statistically significant differences were noted; the mean hemoglobin S level and the reticulocyte count were higher and the
mean hemoglobin level was lower in the group with sickle
cell/p"-thalassemia. Our series included 12 younger patients,
seven with sickle cell/P"''-thalassemia and five with sickle
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Table 2
Clinical Manifestations

Age
No./Mean
Range (years)
Sex
Males
Females
Race
Blacks
Whites
Hepatomegaly
Splenomegaly
Joint pain
Cardiomegaly
Painful episodes
Avascular necrosis of bone
Cholecystectomy, gallstone
Thrombophlebitis
Dactylitis
Retinopathy
Other
Died at young age
Transfusion

Sickle Cell/po-Thalassemia

Sickle Cell/p'''-Thalassemia

12/25
8-52

27/30
1-81

3
9

14
13

12
0
3 (25%)
5 (42%)
7 (58%)
4 (33%)
12 (100%)
0 (0%)
1
2
1
1

24
3
4 (15%)
10 (37%)
11 (41%)
0 (0%)
20 (74%)
4 (15%)
2
1
1
2

2
5

5*

P-value

NS
NS
NS
0.02
NS
NS

(1

NS = not significant.

cell/p^-thalassemia. When considering the influence that age
might have had on the comparative analysis, ie, that more
younger children in one group than the other may have affected
the results of the comparison between the two groups of patients,
our statistical analysis revealed that the age factor did not appear
to influence the comparison.
A fairly wide range of clinical complications was observed in
patients with sickle cell/p"''-thalas!>emia and in those with sickle
cell/p°-thalassemia. Clinical complications were almost as frequent in patients with sickle cell/p+-thalassemia as in those with
sickle cell/p"-thalassemia. With the exception of cardiomegaly,
which was observed more frequently in the sickle cell/p"thalassemia group, there was no statistically significant difference between the two groups with respect to clinical complications. Regarding the laboratory findings, patients with
sickle cell/p^-thalassemia tended to have lower hemoglobins,
higher levels of hemoglobin S, and higher reticulocyte counts
than patients with sickle cell/p+-thalassemia.
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